These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19335279)

  • 1. DCVax-Brain and DC vaccines in the treatment of GBM.
    Wheeler CJ; Black KL
    Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
    Hdeib A; Sloan AE
    CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
    Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
    J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for glioblastoma and high-grade glioma.
    Wheeler CJ; Black KL
    Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First results on the DCVax phase III trial: raising more questions than providing answers.
    Wick W; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
    [No Abstract]   [Full Text] [Related]  

  • 9. Technology evaluation: DCVax, Northwest Biotherapeutics.
    Knutson KL
    Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
    Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
    Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
    Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
    J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.